ArticleOncology letters2022

Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression.

Luigi Grasso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.